OIPE WAR
SEP 3 0 2005
A THANK TO THE TANK OF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re pate	ent application:)	I hereby certify that this correspondence is being deposited with the U. S. Postal Service as first class mail in an envelope addressed to the
Mark Ble	eyer, et al.) Before the Examiner) (Nguyen, D.)	Commissioner for Patents, Alexandria, VA 22313 on September 28, 2005
Serial No	o. 10/025,282)	(Date of Deposit & Signature)
Filed Dec	cember 19, 2001) Group Art Unit) 1632	Kenneth A. Gandy Name of Registered Representative
	PAQUE IMPLANTABLE GENOUS BIOMATERIAL)) Our Ref.: 3433-333)) September 28, 2005	Date of Signature
		N DISCLOSURE STATEME	ENT
	INFORMATION	DISCLOSURE STATEME	
PO Box 1	ioner for Patents		
Sir:			
1. Lis	t of All Patents, Publications, U.S	Applications or Other Info	rmation
references	rsuant to the provisions of 37 CFR 1 s listed on the attached PTO/SB/08 onal information identified below.		
2. En	closed Legible Copies		
a. form is en	A legible copy of each foreign paclosed,	patent document and publication	on listed on the PTO/SB/08
	i. except, a copy is <u>not</u> providing in prior U.S. Patent Application present application claims priority	n Serial No. <u>09/444,881,</u> filed	sly cited by or submitted to the November 22, 1999, from
identified		led for each cumulative refere	ence and enclosed reference
	A copy of the specification and	drawings for each cited unpub	plished U.S. application.
c.	A copy of a Search Report or W	ritten Opinion from a foreign	patent office is also enclosed.
□ d.	Consideration of the enclosed a	dditional and/or below discuss	sed information is requested.

Concise Explanation of Relevance for Non-English Language Information For each non-English language reference listed on the attached SB/08 form(s), reference is made to: 3a. an English language translation submitted herewith, 3b. foreign patent office Search Report (in the English language) submitted herewith, 3c. an English language translation of a foreign patent office Search Report submitted herewith, 3d. the concise explanation contained in the present application at page(s) ______, 3e. the concise explanation set forth in the attached English language abstract, 3f. a copy of a related patent publication (in the English language) submitted herewith, Foreign Patent Document Corresponding English Language Patent Document 3g. the following concise explanation: Time for Filing П 4a. This Information Disclosure Statement is submitted: for U.S. national applications or national stage PCT applications (not including CPAs and RCEs), within 3 months of filing or entry into national stage; or ii. for U.S. national applications, national stage PCT applications, CPAs or RCEs, before the first Office Action on the merits, and thus no certification and/or fee is required. This information Disclosure Statement is submitted after three months from the filing date and after the first Office Action on the merits, but prior to the mailing date of a final Office Action or Notice of Allowance, and thus: the statement specified in 37 CFR §1.97(e) is provided below, or a fee of \$180.00 (set forth in 37 CFR §1.17(p)) is enclosed. This Information Disclosure Statement is submitted after the mailing date of a final Office Action or Notice of Allowance and prior to payment of the issue fee, and thus: the statement specified in 37 CFR §1.97(e) is provided below, and a fee of \$180.00 (set forth in 37 CFR §1.17(p)) is enclosed, or X ii. a Request for Continued Examination (RCE) and fee of 37 CFR §1.17(e) has been filed. Information Disclosure Statement 2 Serial No. 10/025,282

	4d.	Thi	s Information Disclosure Statement is submitted after payment of the issue fee, and thus:
		i.	a Petition to Withdraw from Issue pursuant to 37 CFR §1.313(c)(2) has been filed, and
		ii.	a Request for Continued Examination (RCE) and fee of 37 CFR §1.17(e) has been filed
5	Certi	ficat	ion- Statement Under 37 CFR 1.97(e)
		⁄as fi	hereby certified that each item of information contained in this Information Disclosure rst cited in any communication from a foreign patent office in a counterpart foreign nore than three months prior to the filing of this Information Disclosure Statement.
stater	5b. nent is		opy of a dated communication from a foreign patent office which clearly shows the g submitted within three (3) months of the date on the communication is enclosed.
and, t Infori	nent v o my l nation	vas ci know Disc	hereby certified that no item of information contained in this Information Disclosure ited in a communication from a foreign patent office in a counterpart foreign application ledge after making reasonable inquiry, no item of information contained in this closure Statement was known to any individual designated in §1.56(c) more than three he filing of this Information Disclosure Statement.

The filing of this Information Disclosure Statement shall not be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in §1.56(b). It is believed that no additional fees are required. Should any other fee be required, however, please charge such fee to Deposit Account No. 23-3030, but not to include any payment of issue fees.

Respectfully submitted,

Kenneth A. Gandy, Reg. No. 33,386

Woodard, Emhardt, Moriaty, McNett & Henry LLP

Bank One Center/Tower

111 Monument Circle, Suite 3700 Indianapolis, Indiana 46204-5137

(317) 634-3456

#333159 3433-333 KAG WEMMH/SB/08A (4/03)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

	Complete if Known	
Application Number	10/025,282	
Filing Date	December 19, 2001	
First Named Inventor	Bleyer, M.	
Group Art Unit	1632	
Examiner Name	Nguyen, D	
Attorney Docket Number	3433-333	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant	
		Number-Kind Code ² (If known)			Figures Appear	
		US-2,127,903	08/23/1938	Bowen, A.		
		US-3,562,820	02/16/1971	Braun, B.		
		US-4,795,741	01/03/1989	Leshchiner, et al.		
,		US-4,902,508	02/20/1990	Badylak, et al.	· · · · · · · · · · · · · · · · · · ·	
		US-4,956,178	09/11/1990	Badylak, et al.		
		US-5,139,505	08/18/1992	Palmieri, B.	-	
		US-5,141,747	05/25/1992	Scholz, M.		
		US-5,275,826	01/04/1994	Badylak, et al.		
		US-5,281,422	01/25/1994	Badylak, et al.		
		US-5,372,821	12/13/1994	Badylak, et al.		
		US-5,460,962	10/24/1995	Kemp, P.		
		US-5,554,389	09/10/1996	Badylak, et al.		
		US-5,601,602	02/11/1997	Fowler, B.		
		US-5,609,629	03/11/1997	Fearnot, et al.		
		US-5,676,146	10/14/1997	Scarborough, N.		
		US-5,676,689	10/14/1997	Kensey, et al.		
		US-5,749,894	05/12/1998	Engelson, E.		
		US-5,788,625	08/04/1998	Plouhar, et al.		
		US-5,885,619	03/23/1999	Patel, et al.		
		US-5,942,496	08/24/1999	Bonadio, et al.		
		US-5,997,575	12/07/1999	Whitson, et al.		
		US-5,997,895	12/07/1999	Tarotam, et al.		
		US-6,024,735	02/15/2000	Wolfinbarger, L.		
-		US-6,042,605	03/28/2000	Martin, et al.		
		US-6,048,362	04/11/2000	Berg, T.		
		US-6,096,070	08/01/2000	Ragheb, et al.		
		US-6,099,567	08/08/2000	Badylak, et al.		
		US-6,206,931	03/27/2001	Cook, et al.		
		US-6,358,284	03/19/2002	Fearnot, et al.		
		US-6,475,232	11/05/2002	Babbs, et al.		
		US 2002/0099448	07/25/2002	Hiles, et al.		
		US 2004/0078076	04/22/2004	Badylak, et al.		

#333159 3433-333 KAG WEMMH/SB/08A (4/03) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

December 19, 2001

10/025,282

3433-333

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Application Number

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Filing Date First Named Inventor Bleyer, M. Group Art Unit 1632 **Examiner Name** Nguyen, D

Attorney Docket Number

		Foreign Patent Document			Pages, Columns, Lines, Where	
Examiner Initials*	Cite No.¹	Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Relevant Passages or Relevant Figures Appear	T ⁶
		WO 94/26175	11/24/1994	Vitaphore Corporation		
		WO 95/22611	08/24/1995	The Regents of the University of Michigan		
		WO 96/24661	08/15/1996	Purdue Research Foundation, et al.		
		WO 96/25179	02/16/1996	Purdue Research Foundation		
		WO 96/32146	10/17/1996	Advanced Cytometrix, Inc.		
		WO 97/19643	06/05/1997	Endomatrix, Inc.		
		WO 98/22158	05/28/1998	Cook Biotech, Inc., et al.		
		WO 98/25545	06/18/1998	Cook Biotech, Inc.		
		WO 98/25636	06/18/1998	Purdue Research Foundation		
		WO 98/25637	06/18/1998	Purdue Research Foundation		
		WO 98/26291	06/18/1998	Purdue Research Foundation		
		WO 99/44538	09/10/1999	The Regents of the University of California, et al.		

	1	
Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.s. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the emperor must precede the serial number of the patent document. ⁵ Kind of document by the apopropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

#333172 3433-333 KAG WEMMH/SB/08B (4/03)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known			
Application Number	10/025,282		
Filing Date	December 19, 2001		
First Named Inventor	Bleyer, M.		
Group Art Unit	1632		
Examiner Name	Nguyen, D		
Attorney Docket Number	3433-333		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1					
		American National Standard, ANSI/AAMI 10993-1:1994. "Biological Evaluation of Medical Devices—Part 1: Guidance on Selection of Tests". Association for the Advancement of Medical Instrumentation. pp. 9-17.				
		BALDRY, M.G.C., et al., "Disinfection with Peroxygen", <i>Industrial Biocides</i> , 1988. pp. 91-116, K. Payne, editor. John Wiley and Sons, Inc., New York.				
		BLOCK, S. "Peroxygen Compounds", <i>Disinfection, Sterilization and Preservation</i> , 5 th Edition 2001. pp. 185-204. Lippincott Williams & Wilkins, Philadephia, PA.				
		DENTON, F.W., "Chlorhexidine", <i>Disinfection, Sterilization and Preservation</i> , S. Block, editor, 5 th Edition 2001. pp. 321-336. Lippincott Williams & Wilkins, Philadephia, PA.				
		HORAK, D., et al. "Hydrogels in Endovascular Embolization. III. Radiopaque Spherical Particles, Their Preparation and Properties". <i>Biomaterials</i> , March 1987. Vol. 2, No. 8. pp. 142-145. Butterworth-Heinemann In Association With The Biological Engineering Society, England.				
		KROPP, B.P., et al. "Experimental Assessment of Small Intestinal Submucosa as a Bladder Wall Substitute". <i>Urology</i> , 1995. Vol. 46, No. 3. pp. 396-400. Elsevier Science, United States.				

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.